Biomedikos centras - Company finances
|
EUR
|
2018
From: 2018-10-31
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 646,682 | 3,723,684 | 4,489,876 | 4,857,656 | 5,141,862 | 7,062,452 | 6,415,754 | 8,359,657 |
| Profit before tax | 21,160 | 40,686 | 201,752 | 138,303 | -102,782 | 379,512 | 128,955 | -1,030,246 |
| Net profit | 12,969 | 28,248 | 164,917 | 113,933 | -138,016 | 320,190 | 99,448 | -1,030,756 |
| Equity | 196,547 | 224,795 | 389,712 | 503,645 | 365,629 | 685,819 | 785,267 | 1,004,512 |
| Liabilities | 1,428,943 | 1,246,906 | 1,201,870 | 1,166,986 | 1,092,033 | 994,173 | 1,211,374 | 2,022,323 |
| Non-current assets | 89,932 | 209,830 | 261,500 | 205,389 | 269,234 | 216,906 | 364,704 | 649,442 |
| Current assets | 1,521,851 | 1,258,375 | 1,316,154 | 1,433,312 | 1,173,318 | 1,445,829 | 1,603,713 | 2,344,597 |
| Total assets | 1,611,783 | 1,468,205 | 1,577,654 | 1,638,701 | 1,442,552 | 1,662,735 | 1,968,417 | 2,994,039 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 752,250 | 734,852 | 694,183 |
| Social insurance contributions | - | - | - | - | - | 278,466 | 331,994 | 493,458 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +475.8% | +20.6% | +8.2% | +5.9% | +37.4% | -9.2% | +30.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.8% | 1.9% | 10.5% | 7.0% | -9.6% | 19.3% | 5.1% | -34.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 6.6% | 12.6% | 42.3% | 22.6% | -37.7% | 46.7% | 12.7% | -102.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.0% | 0.8% | 3.7% | 2.3% | -2.7% | 4.5% | 1.6% | -12.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.3% | 1.1% | 4.5% | 2.8% | -2.0% | 5.4% | 2.0% | -12.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 7.3 | 5.5 | 3.1 | 2.3 | 3.0 | 1.4 | 1.5 | 2.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 28,741 | 147,473 | 164,766 | 161,474 | 159,850 | 241,451 | 196,400 | 167,472 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biomedikos centras - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-08-17 | 2023-08-27 | 0.31 |
| 2023-07-26 | 2023-08-13 | 0.31 |
| 2023-07-24 | 2023-07-25 | 0.32 |
Biomedikos centras - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-11-22 | 2025-11-24 | 95.23 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biomedikos centras, UAB (code 304943503) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €8.36M, up 30.3% year on year and 18.4% over two years. However, profitability weakened sharply: net profit was -€1.03M, compared with €99.4K in 2024 and €320.2K in 2023. The 2025 profit margin was -12.3%, reflecting a substantial loss after two profitable years. The balance sheet expanded during the period, with total assets rising to €2.99M in 2025 from €1.97M in 2024 and €1.66M in 2023. Equity increased to €1.00M, while liabilities reached €2.02M. The equity ratio stood at 33.5% and debt-to-equity at 2.01. Asset turnover was 2.79x, indicating strong revenue generation relative to assets. Revenue per employee was €170.6K, while profit per employee was -€21.0K in 2025. Overall, the company combined higher sales with a significantly weaker bottom line in the latest year.